$521K
1 filing since 2024 · latest Equity filed
EmGenisys develops non-invasive embryo analysis technology for livestock reproductive programs. Its platform captures a short video of embryos in culture media through a smartphone mounted on a standard microscope and uses machine learning and computer vision to score embryo health and viability in seconds. The assessment is designed to run either in the lab or chute-side, replacing subjective visual grading with objective, data-driven output. The company was founded by veterinary and animal-science researchers and won the BioTools Innovator grand prize in 2024.
What sets it apart
Assesses embryo health non-invasively from a 30-second smartphone video on equipment breeders already own, returning objective viability results in seconds where the industry standard is subjective visual grading by an embryologist.
A software platform that analyzes a 30-second video of embryos in culture media, captured via a smartphone on a standard microscope, and returns a machine-learning-derived health and viability assessment.
